SCHEMBL4517754

SCHEMBL4517754

O=c1[nH]nc2c3cc(-c4cn[nH]c4)ccc3ccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.47
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
ACVR1 Q04771 1/20 0.42
ROCK2 O75116 3/20 0.40
FLT3 P36888 2/20 0.39
GRK2 P25098 2/20 0.39
ROCK1 Q13464 2/20 0.39
AURKA O14965 1/20 0.39
RPS6KA1 Q15418 1/20 0.39
LTK P29376 2/20 0.38
ALK Q9UM73 2/20 0.38
DYRK1B Q9Y463 2/20 0.38
GRK5 P34947 2/20 0.38
DAPK3 O43293 1/20 0.38
ABL1 P00519 1/20 0.38
PRKACA P17612 1/20 0.38
KDR P35968 1/20 0.38
LIMK1 P53667 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4517652 0.82 LTK (0.39) CHEK1PIM1PIM2ROCK1LTK
SCHEMBL4509185 0.81 CHEK1 (0.44) CHEK1ROCK1LTKALKDYRK1B
SCHEMBL4506161 0.79 CHEK1 (0.47) CHEK1PIM1ACVR1ROCK1AURKA
SCHEMBL4239492 0.78 PRMT5 (0.49) CHEK1ACVR1DYRK1AMETLRRK2
SCHEMBL4496917 0.78 CHEK1 (0.47) CHEK1PIM1PIM2ROCK1LTK
SCHEMBL4491588 0.78 CHEK1 (0.40) CHEK1ROCK1LTKALKDYRK1B
SCHEMBL4499252 0.78 CHEK1 (0.47) CHEK1ROCK1LTKALKDYRK1B
SCHEMBL4510609 0.77 GSK3A (0.39) CHEK1ROCK1LTKALKDYRK1B
SCHEMBL4240405 0.76 PRMT5 (0.50) LTKALKDYRK1BGRK5DYRK1A
SCHEMBL4517378 0.75 QPCT (0.46) CHEK1ROCK1LTKALKDYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
US-7501435-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-03-10 US disclosed
WO-2007127138-A1 TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-11-08 WO disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed
US-20070254879-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254879-A1 Inhibitors of checkpoint kinases CHEK1, CHEK2, PLK1 CHEK1 1/4885PIM1 1009/4885PIM3 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.